Vitamin D supplementation decreases the occurrence of acute phase response following i.v. bisphosphonate treatment in Paget's disease of bone

2014 ◽  
Author(s):  
Daniela Merlotti ◽  
Luigi Gennari ◽  
Maria Beatrice Franci ◽  
Barbara Lucani ◽  
Maria Stella Campagna ◽  
...  
Keyword(s):  
Vitamin D ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Vitamin D Supplementation ◽  
Paget’S Disease Of Bone ◽  
Phase Response ◽  
Paget's Disease Of Bone ◽  
Bisphosphonate Treatment

Abnormalities of Vitamin D Metabolism in Paget's Disease of Bone

1983 ◽  
Vol 64 (2) ◽  
pp. 65P-65P
Author(s):  
D.F. Guilland-Cumming ◽  
P.J. Lawson-Matthew ◽  
S.K. Johnson ◽  
D.J. Beard ◽  
A. Yates ◽  
...  
Keyword(s):  
Vitamin D ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Vitamin D Metabolism

ABNORMAL VITAMIN D METABOLISM IN PAGET'S DISEASE OF BONE

1985 ◽  
Vol 22 (4) ◽  
pp. 559-566 ◽  
Author(s):  
D. F. GUILLARD-CUMMING ◽  
D. J. BEARD ◽  
D. L. DOUGLAS ◽  
S. K. JOHNSON ◽  
P. J. LAWSON-MATTHEW ◽  
...  
Keyword(s):  
Vitamin D ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Vitamin D Metabolism

scholarly journals Prevalence of vitamin D deficiency is higher in patients with Paget's disease of bone compared with age-matched controls

2013 ◽  
Vol 57 (7) ◽  
pp. 509-512 ◽  
Author(s):  
Luiz Griz ◽  
Francisco Bandeira ◽  
Erik Trovão Diniz ◽  
Marcelo Cabral ◽  
Eduardo Freese
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Postmenopausal Women ◽  
Paget’S Disease ◽  
Hypovitaminosis D ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Elderly Men ◽  
Control Groups

OBJECTIVE: To investigate if vitamin D deficiency is more prevalent in patients with Paget's disease of bone (PDB) than in age-matched controls. SUBJECTS AND METHODS: We measured serum 25-OHD in 28 untreated patients with PDB and two control groups: 284 elderly men from an ongoing cohort from our department, and 151 postmenopausal women seen in our outpatient clinic for routine medical evaluation. RESULTS: The mean ± SD serum 25-OHD was significantly lower in subjects with PDB (23.76 ± 6.29 ng/mL) than in the control groups of elderly men (27.86 ± 13.52 ng/mL) and postmenopausal women (30.30 ± 9.59 ng/mL), p = 0.015. The prevalence of vitamin D deficiency considering a cut-off point of serum 25-OHD < 30 ng/mL was 85.7% in patients with PDB, and in elderly men and postmenopausal women it was 66.7 % and 54.3%, respectively (p < 0.001). CONCLUSION: These results suggest a high prevalence of hypovitaminosis D in patients with Paget's disease living in the tropics.

scholarly journals Randomized trial of intensive bisphosphonate treatment versus symptomatic management in paget's disease of bone

2009 ◽  
Vol 25 (1) ◽  
pp. 20-31 ◽  
Author(s):  
Anne L Langston ◽  
Marion K Campbell ◽  
William D Fraser ◽  
Graeme S MacLennan ◽  
Peter L Selby ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Bisphosphonate Treatment ◽  
Symptomatic Management

Paget’s Disease of Bone and Calcium Homeostasis: Focus on Bisphosphonate Treatment

2011 ◽  
Vol 119 (09) ◽  
pp. 519-524 ◽  
Author(s):  
S. Polyzos ◽  
A. Anastasilakis ◽  
P. Makras ◽  
E. Terpos
Keyword(s):  
Vitamin D ◽  
Secondary Hyperparathyroidism ◽  
Vitamin D Deficiency ◽  
Bone Disease ◽  
Bone Mineralization ◽  
Paget’S Disease ◽  
The Elderly ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone

AbstractPaget’s disease of bone (PDB) is the second most common metabolic bone disease. Bisphosphonates (BPs) are currently the drugs of choice for PDB. PDB and osteomalacia are both common in the elderly. The concept of relative vitamin D deficiency in patients with PDB was suggested long ago, but it has not yet elucidated. Both diseases predispose to fractures, but their combined action to fragility has not been studied yet. The older BPs, mainly etidronate, further inhibit bone mineralization. Mineralization defects have also been described in patients with PDB treated with pamidronate. Moreover, hypocalcemia and secondary hyperparathyroidism after treatment with BPs have been described in PDB. Hypocalcemia seems to be more severe after treatment with the more potent, intravenous zoledronic acid, which is currently the treatment of choice for PDB. The counteracting hyperparathyroidism pathophysiologically intends to increase renal reabsorption of calcium and 1.25-dihydroxy vitamin D production and to stimulate osteoclasts in order to prevent long-term hypocalcemia. However, the effect of PTH on osteoclasts is, at least partly, restricted in patients taking BPs. Secondary hyperparathyroidism is a potentially detrimental condition, especially in patients already suffering from another bone disease. Serum calcium and vitamin D deficiency should be restored before BP treatment and calcium and vitamin D administration should be possibly continued for longer after achieving normocalcemia, which may shorten the duration of secondary hyperparathyroidism.Mineralization defects and hypocalcemia with secondary hyperparathyroidism have been described in patients with Paget’s disease of bone treated with bisphosphonates. Secondary hyperparathyroidism may be a potentially detrimental condition for patients with Paget’s disease of bone.

Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone

Bone ◽  
2006 ◽  
Vol 39 (4) ◽  
pp. 954-958 ◽  
Author(s):  
Heather E. Whitson ◽  
Bruce Lobaugh ◽  
Kenneth W. Lyles
Keyword(s):  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Bisphosphonate Treatment

scholarly journals Paget’s disease of bone, biphosphonates and jaw osteonecrosis: a case report

NEMESIS ◽  
2019 ◽  
Vol 4 (1) ◽  
pp. 15
Author(s):  
Michele Magremanne ◽  
Anne Grysolle ◽  
Hervé Reychler
Keyword(s):  
Case Report ◽  
Paget’S Disease ◽  
Rare Event ◽  
Rare Condition ◽  
Osteonecrosis Of The Jaw ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Bisphosphonate Treatment ◽  
Oncologic Patients

Objective: Paget’s disease of bone is characterized by a focal increase in bone resorption and accelerated bone formation leading to a weaker and disorganised bone. Bisphosphonates (BPs) have been the treatment of choice of Paget’s disease since the 1990s. Medication related osteonecrosis of the jaw (MRONJ) is a rare event in non oncologic patients. We describe a rare case of  Paget’s disease involving the maxilla with osteonecrosis in a context of bisphosphonate treatment.   Case report: an 87-year-old woman presented with 4 episodes of bone necrosis in 15 years. In this case report there is a clear chronologic association between the occurrence of MRONJ and the administration of iv BP for Paget’s disease. Maxillofacial involvement of Paget’s disease occurs in less than 15% of cases. There is a lack of information in the literature about the association of MRONJ and Paget’s disease. Even if osteonecrosis of the jaw could be a consequence of the disease, in this case, it is more in relation to the BP treatment.   Conclusions: Although MRONJ might be considered a rare condition in Paget’s disease, patients prior to starting antiresorptive therapy and in particular iv BPs should have a complete dental examination and panoramic X-Ray.   Nemesis relevance: side effect of bisphosphonate treatment  

scholarly journals Computer-assisted quantitative evaluation of bisphosphonate treatment for Paget's disease of bone using the bone scan index

2016 ◽  
Vol 12 (6) ◽  
pp. 3830-3836 ◽  
Author(s):  
Satoshi Nagano ◽  
Shunsuke Nakamura ◽  
Hirofumi Shimada ◽  
Masahiro Yokouchi ◽  
Takao Setoguchi ◽  
...  
Keyword(s):  
Quantitative Evaluation ◽  
Bone Scan ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Computer Assisted ◽  
Paget's Disease Of Bone ◽  
Bisphosphonate Treatment ◽  
Bone Scan Index
Sign in / Sign up

Export Citation Format

Share Document